Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ARRon Apr 19, 2013 4:34pm

82 Views

Post# 21276719

RE: RE: RE: RE: RE: Twilight Zone

YJonzobot - are you serious?

"The assets of RVX are owned by RVX to do with as RVX chooses. "

Who owns RVX? The shareholders do.

You are right, future royalties are an asset. If RVX "sells" the future royalties to Spinco, how does Spinco pay for them? and where does that payment go?

to RVX shareholders and that is us.

Bullboard Posts

Xplore Resources to expand position near Surge Lithium Project